急诊科急性未分化激越的肌注氟哌利多、齐拉西酮与劳拉西泮随机双盲试验
本研究为随机双盲试验,纳入急诊需胃肠外镇静的急性激越患者115例,比较肌注氟哌利多5 mg、齐拉西酮10 mg、齐拉西酮20 mg及劳拉西泮2 mg的效果与安全性。主要终点为15分钟时充分镇静(AMSS≤0)的比例,氟哌利多组为64%,高于齐拉西酮10 mg组25%、齐拉西酮20 mg组35%及劳拉西泮组29%。氟哌利多较齐拉西酮20 mg多39%(95%CI 3%~54%),较劳拉西泮多33%(95%CI 8%~58%)。各组需追加镇静无显著差异;呼吸抑制例数氟哌利多组数值上更低(12% vs 36%、39%、48%),无室性心律失常,QTc相似。
要点
- 急诊急性激越需胃肠外镇静成人患者中,肌注氟哌利多5 mg在15分钟时充分镇静率64%(16/25),高于劳拉西泮2 mg的29%(9/31)。
- 氟哌利多5 mg较齐拉西酮20 mg充分镇静率高39%(95%CI 3%~54%),较劳拉西泮2 mg高33%(95%CI 8%~58%)。
- 呼吸抑制发生率氟哌利多组12%(3/25),数值上低于齐拉西酮10 mg组36%(10/28)、齐拉西酮20 mg组39%(12/31)及劳拉西泮组48%(15/31)。
- 各组需追加补救镇静无显著差异;无患者发生室性心律失常,各组QTc时长相似。
- 1例接受齐拉西酮20 mg的患者因急性硬膜下血肿需插管处理。
适用人群与场景
- 急诊科急性激越且需胃肠外镇静的患者。
- 研究在免除知情同意(21 CFR 50.24)下进行,时间为2004年7月至2005年3月。
诊断标准与关键阈值
- 采用改良精神状态量表(AMSS)评估镇静程度,主要终点为15分钟时AMSS≤0(充分镇静)。
- 呼吸抑制定义为ETCO2变化符合呼吸抑制或SpO2<90%。
处置流程与药物剂量
- 随机分组接受单次肌注:氟哌利多5 mg、齐拉西酮10 mg、齐拉西酮20 mg或劳拉西泮2 mg。
- 在0、15、30、45、60、90、120分钟记录AMSS评分、鼻端呼气末二氧化碳(ETCO2)及脉搏血氧饱和度(SpO2),并监测QTc时长及心律失常。
红旗征与不能漏的情况
- 1例接受齐拉西酮20 mg的患者因急性硬膜下血肿需插管处理。
研究设计与关键结果
- 随机双盲试验纳入115例急诊急性激越患者,各组基线AMSS评分相似。
- 15分钟充分镇静率:氟哌利多5 mg组64%(16/25) vs 齐拉西酮10 mg组25%(7/28)、齐拉西酮20 mg组35%(11/31)、劳拉西泮2 mg组29%(9/31)。
- 氟哌利多较齐拉西酮20 mg充分镇静率高39%(95%CI 3%~54%),较劳拉西泮高33%(95%CI 8%~58%)。
- 需追加补救镇静各组无显著差异。
- 呼吸抑制例数:氟哌利多组12%(3/25)、齐拉西酮10 mg组36%(10/28)、齐拉西酮20 mg组39%(12/31)、劳拉西泮组48%(15/31)。
- 无患者发生室性心律失常,各组QTc时长相似。
证据类型、等级与局限
- 证据类型:随机双盲试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于急诊急性激越需胃肠外镇静的成人患者,肌注氟哌利多5 mg在15分钟充分镇静上优于肌注劳拉西泮2 mg及齐拉西酮10 mg或20 mg,且呼吸抑制更少。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The optimal agent to treat acute agitation in the emergency department (ED) has not been determined. The objective of this study was to compare the effectiveness and safety of intramuscular droperidol, ziprasidone, and lorazepam for acute agitation in the ED.
METHODS: This was a randomized, double-blind trial of ED patients with acute agitation requiring parenteral sedation. The study was conducted under exception from informed consent (21 CFR 50.24) from July 2004 to March 2005. Patients were randomized to receive 5 mg of droperidol, 10 mg of ziprasidone, 20 mg of ziprasidone, or 2 mg of lorazepam intramuscularly. We recorded Altered Mental Status Scale (AMSS) scores, nasal end-tidal carbon dioxide (ETCO2 ), and pulse oximetry (SpO2 ) at 0, 15, 30, 45, 60, 90, and 120 minutes as well as QTc durations and dysrhythmias. Respiratory depression was defined as a change in ETCO2 consistent with respiratory depression or SpO2 < 90%. The primary outcome was the proportion of patients adequately sedated (AMSS ≤ 0) at 15 minutes.
RESULTS: We enrolled 115 patients. Baseline AMSS scores were similar between groups. For the primary outcome, adequate sedation at 15 minutes, droperidol administration was effective in 16 of 25 (64%) patients, compared to seven of 28 (25%) for 10 mg of ziprasidone, 11 of 31 (35%) for 20 mg of ziprasidone, and nine of 31 (29%) for lorazepam. Pairwise comparisons revealed that droperidol was more effective that the other medications, with 39% (95% confidence interval [CI] = 3% to 54%) more compared to 20 mg of ziprasidone and 33% (95% CI = 8% to 58%) more compared to lorazepam. There was no significant difference between groups in need of additional rescue sedation. Numerically, respiratory depression was lower with droperidol (3/25 [12%]) compared to 10 mg of ziprasidone (10/28 [36%]), 20 mg of ziprasidone (12/31 [39%]), or lorazepam (15/31 [48%]). One patient receiving 20 mg of ziprasidone required intubation to manage an acute subdural hematoma. No patients had ventricular dysrhythmias. QTc durations were similar in all groups.
CONCLUSIONS: Droperidol was more effective than lorazepam or either dose of ziprasidone for the treatment of acute agitation in the ED and caused fewer episodes of respiratory depression.
参考来源
- Martel ML, Driver BE, Miner JR, et al. Randomized Double-blind Trial of Intramuscular Droperidol, Ziprasidone, and Lorazepam for Acute Undifferentiated Agitation in the Emergency Department. Acad Emerg Med. 2020. PMID: 32888340. doi:10.1111/acem.14124
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。